SOURCE: Source MDx

May 03, 2007 14:32 ET

Source MDx to Participate in Breakout Session Focused on Companion Diagnostics at the 2007 BIO International Convention

BOULDER, CO -- (MARKET WIRE) -- May 3, 2007 -- Source MDx, a molecular diagnostics company, announced today that it will be participating in a session entitled "Twinning" Strategies: The Business of Companion Diagnostics and Targeted Therapies at the 2007 BIO International Convention. Karl Wassmann, CEO and President, will provide an overview of the benefits of biomarkers and companion diagnostics, and discuss how these tools can enable pharmaceutical and biotech companies to economically develop targeted therapies.

The breakout session will take place on Sunday, May 6, 2007 from 4:00 - 5:30 p.m. at the Boston Convention & Exhibition Center in Room 205B.

About Source MDx

Source MDx uses its patented molecular diagnostic system to monitor an individual's health, disease status and response to therapy at the molecular level, using RNA from whole blood or tissue samples. Source MDx markets over 20 patented disease and pathway-specific biomarker panels that are used in both preclinical and clinical drug development, and is developing companion patient care diagnostics focused on oncology, cardiovascular, inflammation and immune response genes. Source MDx OncoProfiling biomarker services for targeted cancer therapy development include the capture and enrichment of live Circulating Tumor Cells (CTCs) and Circulating Endothelial Cells (CECs) for off-line high-precision gene expression analysis with over 850 validated and patented targeted gene assays. The company has completed over 150 preclinical and clinical projects for more than 30 leading pharmaceutical, biotechnology and diagnostic companies, with over one million gene expression measurements analyzed.

Contact Information